Virtual | September 23-25, 2021
THURSDAY, SEPTEMBER 23, 2021
8:00 AM – 10:29 AM
SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
State of the Art in Prostate Cancer Screening
Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
11:00 AM – 12:40 PM
Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling (Continued)
NCCN Guidelines for Early Detection of Prostate Cancer 2021
Integrated Multi-Modality Diagnostic Evaluation
12:40 PM – 2:30 PM
LUNCH BREAK
2:30 PM – 3:29 PM
SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Liquid Markers
Tissue-Based Genetic Cancer Profiling
Biopsy
3:59 PM – 6:00 PM
SESSION II. CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Pathology Overview
In Vivo Imaging and Digital Health
FRIDAY, SEPTEMBER 24, 2021
8:00 AM – 10:00 AM
SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)
In Vivo Imaging and Digital Health (Continued)
10:20 AM – 11:34 AM
Integration of Precision Diagnosis and Precision Treatment
11:34 AM – 1:19 PM
LUNCH BREAK
1:19 PM – 3:40 PM
SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
4:00 PM – 6:00 PM
Molecular and Multi-Modality Imaging and Theranostics
SATURDAY, SEPTEMBER 25, 2021
8:00 AM – 9:30 AM
SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT
Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
10:00 AM – 11:00 AM
Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes (Continued)
11:00 AM – 1:00 PM
LUNCH BREAK
1:00 PM – 1:45 PM
PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
1:45 PM – 3:30 PM
PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTIMODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT
3:30 PM – 3:50 PM:
PRESENTATION OF WINNING ABSTRACTS
3:50 PM – 5:30 PM
SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS
5:30 ADJOURN
8:15 am SESSION I: PATIENT POPULATION PRIOR TO DIAGNOSIS OF PROSTATE CANCER: SCREENING AND CLINICAL EVALUATION OF MEN WITH CLINICAL SUSPICION
Moderators:
Jim C. Hu, MD, MPH, Ronald P. Lynch Professor of Urologic Oncology and Professor of Urology, Weill Cornell Medical College, Cornell University; and Attending Urologist, New York-Presbyterian Hospital
Grannum Sant, MD, FRCS, FACS, Professor and Former Chair of Urology, Tufts University School of Medicine; Former Head, Oncology/Urology Medical Affairs, Sanofi, and Rare Genetic Diseases, Genzyme
.
Clare M. C. Tempany-Afdhal, MB BAO BCh, FACR, FISMRM, Ferenc Jolesz MD Professor of Radiology Harvard Medical School; Vice-Chair, Radiology Research Brigham & Women’s Hospital; Director of the Ferenc Jolesz National Center for Image-Guided Therapy & AMIGO; and Chair, Joint American College of Radiology, AdMeTech Foundation and European Society of Urogenital Radiology Steering Committee on PI-RADS Standardization
8:30 am Topic 1: State of the Art in Prostate Cancer Screening
Sigrid Carlsson, MD, PHD, MPH, Assistant Attending Epidemiologist, Departments of Surgery (Urology Service) and Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center and Associate Professor of Experimental Urology, Sahlgrenska Academy, Gothenburg University, Sweden
8:42 am Q & A
8:44 am Topic 2: Current and Emerging Diagnostic Tools for Improving Risk Assessment, Selection of Patients for Biopsy and Tissue Sampling
8:44 am Topic 2A: Current and Emerging Liquid Diagnostics
8:44 am Keynote Address – Clinical Perspective on Current and Emerging Liquid Diagnostics
E. David Crawford, MD, Professor of Urology, University of California San Diego; Chairman, Prostate Conditions Education Council; Editor in Chief, Grand Rounds in Urology; and Prostate Cancer Series Editor, Oncology Journal
8:56 am Q & A
8:58 am Sponsored by OPKO Health – Clinical Value of 4KScore
Peter Scardino, MD, David Koch Chair, Department of Surgery, Memorial Sloan Kettering Cancer Center; David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Visiting Professor of Urology SUNY Downstate Health Sciences University, College of Medicine; andGregory Thoreson, MD – Urologist, Urology Clinics of North Texas
9:04 am IsoPSA®: Clinical Performance of a Single Parameter, Structure Based Test for High Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial
Eric A. Klein, MD, Chairman, Glickman Urological and Kidney Institute, and Staff Member, Taussig Cancer Institute, Cleveland Clinic
9:10 am Q & A
9:12 am Liquid Biopsy
Laurence Klotz, MD, Professor of Surgery, University of Toronto and Chair of Prostate Cancer Research, Sunnybrook Medical Center, University of Toronto; and Chair, World Urologic Oncology Federation
9:24 am Q & A
9:26 am – 9:37 am Panel Discussion – Liquid Biomarkers
Speakers and Mark Katz, MD, Assistant Professor of Surgery, Boston University School of Medicine
9:37 am Topic 2B: The Re-Emergence of Transperineal Prostate Biopsy – Current and Future Clinical Role
Edward Schaeffer, MD, PhD, Edmund Andrews Professor and Chair, Department of Urology, Northwestern University
.
9:49 am Q & A
9:54 am Topic 2C: Current and Emerging Imaging Tools and Targeted Biopsies
9:54 am Advanced Ultrasound
9:54 am Real-Time High-Resolution Micro-Ultrasound
9:54 am Radiologic Perspective
Sangeet Ghai, MD, Associate Professor, Department of Medical Imaging, University of Toronto, Canada
10:06 am Urologic Perspective
Rafael Sanchez-Salas, MD, Associate Professor, Department of Surgery, Division of Urology, McGill University, Canada
10:12 am Q & A
10:14 am Contrast-Enhanced Ultrasound
Ethan Halpern, MD, Professor and Vice Chair for Research; CoDirector, Prostate Diagnostic Center; and Director, Cardiac CT, Thomas Jefferson University
10:26 am Q & A
10:29 am – 11:00 am COFFEE BREAK
11:00 am Multi-Parametric (mp) and Bi-Parametric (bp) Magnetic Resonance Imaging
11:00 am Recent Advancements in PI-RADS – Risk Assessment with mpMRI vs bpMRI
Jelle Barentsz, MD, PhD, Chair and Professor of Radiology, Prostate MR Center of Excellence, Nijmegen Medical Center, Radboud University, The Netherlands; and Founding Member and Past-President of the International Cancer Imaging Society, and Past-President of the European Society of Urogenital Radiology
.
11:12 am Q & A
11:14 am American College of Radiology Prostate MRI Image Quality Initiative
Jeffrey Weinreb, MD, Professor, Department of Diagnostic Radiology and Biomedical Imaging, Yale School of Medicine and Chief of MRI Services, Yale-New Haven Hospital
.
11:24 am Q & A
11:26 pm Prostate Imaging Elevated by Deep Learning
.Mukesh Harisinghani, MD, Director of Abdominal MRI, Massachusetts General Hospital and Professor of Radiology, Harvard Medical School
Ersin Bayram, PhD, Director, Body and Oncology MRI, GE Healthcare
.11:44 am Q & A
11:46 am MRI-targeted Biopsy of the Prostate
11:46 am Optimizing Patient Selection and Technique
Fergus Coakley, MD, Professor and Chair of Radiology, School of Medicine, Oregon Health and Science University
11:58 am Q & A
12:01 pm Transperineal Biopsy & Classification of Risk Using Novel Gleason Pattern Quantification
Behfar Ehdaie, MD, MPH, Urologic Surgeon, Memorial Sloan Kettering Cancer Center
12:07 pm – 12:17 pm Panel Discussion: Imaging Modalities and Targeted Biopsies
12:17 pm Topic 3: NCCN Guidelines for Early Detection of Prostate Cancer 2021
Preston Sprenkle, MD, Assistant Professor of Surgery, Yale University School of Medicine; and Member, NCCN Prostate Cancer Early Detection Panel
12:23 pm Q & A
12:25 pm Topic 4: Integrated Multi-Modality Diagnostic Evaluation
Robert E. Reiter, MD, MBA, Bing Professor in Prostate Cancer; Director, Prostate Cancer Program and Chief, Division of Urologic Oncology; Assistant Dean, Bioentrepreneurship; Department of Urology, David Geffen School of Medicine at UCLA Institute of Urologic Oncology
12:37 pm Q & A
12:40 pm – 2:30 pm LUNCH BREAK
2:30 pm SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER
Moderators:
Matthew R. Cooperberg, MD, MPH, Professor of Urology and Epidemiology & Biostatistics and Associate Chair for Clinical Research, Department of Urology; Helen Diller Family Chair in Urology, UCSF
.
Masoom Haider, MD, Professor of Radiology, University of Toronto; Senior Clinician Scientist, Lunenfeld Tanenbaum Research Institute; Director, Machine Learning and Radiomics Lab; and Director, Sinai Health System Research MRI, Canada
.
Alan Pollack, MD, PhD, Professor and Chairman of Radiation Oncology, University of Miami Miller School of Medicine; Interim Deputy Director, Sylvester Comprehensive Care Center; and Service Chief, Radiation Oncology, Jackson Memorial Hospital (Invited)
.
Laurence Klotz, MD
.
.
2:45 pm Topic 1: Liquid Markers – Germline Genome and Prostate Cancer Evolution and Aggressivity
Paul Boutros, PhD, MBA, Director of Cancer Data Science, Jonsson Comprehensive Cancer Center; Associate Director of Cancer Informatics at the Institute for Precision Health; and Professor of Urology and Human Genetics, UCLA
2:57 pm Q & A
2:59 pm Topic 2: Overview of Tissue-Based Genetic Cancer Profiling
3:12 pm Q & A
3:14 pm Topic 3: Biopsy
3:14 pm Public Health Perspective on Targeted MRI Biopsy and Overtreatment
Andrew Vickers, PhD, Attending Research Methodologist, Memorial Sloan- Kettering Cancer Center
.
3:25 pm Q & A
3:29 pm – 3:59 pm COFFEE BREAK
3:59 pm Topic 4: Pathology Overview
Thomas Wheeler, MD, Chief of Pathology and Laboratory Medicine, Baylor St. Luke’s Medical Center, and W. L. Moody, Jr. Endowed Chair, Professor and Senior Vice Chair, Department of Pathology & Immunology, Baylor College of Medicine
.
4:11 pm Q & A
4:14 pm – 4:25 pm Panel Discussion: Liquid Markers and Tissue Sampling and Analysis
4:25 pm Topic 5: In Vivo Imaging and Digital Health
4:40 pm Experience with 18F-rhPSMA7.3
Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum der Isar, Technical University of Munich, Germany
4:46 pm Q & A
4:48 pm Topic 5B: Doctor Knows Best? Why Prostate Cancer Care Must Be Transformed into Digital Health
.Michael Johnson, MD, Director, Advanced Cancer Care Center, Oregon Institute of Urology
.
.
.
5:08 pm – 5:20 pm Panel Discussion: Prostate Imaging and Digital Health
5:20 pm – 6:00 pm GENERAL DISCUSSION
8:00 am SESSION II: CLINICAL EVALUATION AND MANAGEMENT OF MEN WITH LOCALIZED AND RECURRENT PROSTATE CANCER (Continued)
Moderators:
Andrei H. Iagaru, MD, FACNM, Professor of Radiology – Nuclear Medicine Chief, Division of Nuclear Medicine and Molecular Imaging Co-Director, PET-MRI Research Program Stanford University
Adam Kibel, MD, Elliott Carr Cutler Professor of Surgery, Harvard Medical School; Chief of Urology, Brigham and Women’s Hospital and Dana-Farber Cancer Institute
.
Kelvin A. Moses, MD, PhD, FACS, Associate Professor of Urology, Urologic Oncology Fellowship Director, and Director of Comprehensive Prostate Cancer Clinic, Vanderbilt University Medical Center, and Chair, NCCN Prostate Cancer Early Detection Guidelines Panel
Lalitha K. Shankar, MD, PhD, Chief, Clinical Trials Branch, Cancer Imaging Program, National Cancer Institute
.
8:00 am Topic 5C: Molecular and Multi-Modality Imaging
8:14 am PSMA Imaging – Emerging Clinical Applications from Radiologic Perspective
Steven Rowe, MD, PhD, Associate Professor of Radiology and Radiologic Science, Johns Hopkins University School of Medicine
8:25 am Q & A
8:27 am PSMA PET/CT Imaging – Emerging Clinical Applications from Urologic Perspective
Neal Shore, MD, FACS, Director, CPI, Carolina Urologic Research Center; Chief Surgical Officer and Head of Urology Research, Genesis Care, US; Founding Director, CUSP: Clinical Research Consortium, Myrtle Beach, SC
9:03 am Q & A
9:07 am Clinical Utility of Axumin
Gerald L. Andriole, MD, Robert Royce Distinguished Professor, Chief of Urologic Surgery, and Vice-Chair, Department of Surgery, Washington University School of Medicine, Barnes-Jewish Hospital, Siteman Cancer Center; and Member, National Comprehensive Cancer Network (NCCN)’s Cancer Early Detection Panel
9:19 am Q & A
9:21 am Neuroendocrine Tumors Imaging and Radionuclide Treatment
Thomas Hope, MD, Associate Professor of Radiology and Director of Molecular Therapy in the Department of Radiology and Biomedical Imaging; Chair of the Cancer Center’s Molecular Imaging & Radionuclide Therapy Site Committee, University of California, San Francisco; Chief of Nuclear Medicine at the San Francisco VA Medical Center
9:33 am Q & A
9:36 am Urologic Perspective on the Current and Emerging Role of Multi-Modality Imaging and Radiogenomics
Mohummad Minhaj Siddiqui, MD, Associate Professor of Surgery, Director of Urologic Oncology and Robotic Surgery, University of Maryland Medical System, and Chief of Urology, Baltimore VA Medical Center; and Participant, US Vice President Joseph Biden’s Cancer Moonshot Program
9:47 am Q & A
9:49 am – 10:00 am Panel Discussion: Imaging Modalities and Radiogenomics
10:00 am – 10:20 am COFFEE BREAK
10:20 am Topic 6: Integration of Precision Diagnosis and Precision Treatment
10:20 am Topic 6A: Integrated Diagnostics (Radiogenomics) and Patient Selection for Active Surveillance vs. Immediate Treatment
Sanoj Punnen, MD, MAS, Co-Chair of Genitourinary Site Disease Group, Pap Corps Champions for Cancer Research Endowed Chair in Solid Tumor Research and Associate Professor, Department of Urology, University of Miami, Miller School of Medicine
10:32 am Q & A
10:34 am Topic 6B: Selection and Monitoring of Image-Targeted Minimally Invasive Treatment
Fiona Fennessy, MB, Bch, PhD, Associate Professor of Radiology, Harvard Medical School; Faculty Radiologist, Brigham & Women’s Hospital; Program Director, Cancer Imaging Fellowship Program; and Institute Physician, Dana-Farber Cancer Institute
10:45 am Q & A
10:47 am Topic 6C: Overview of Role of Imaging for Precision Radiation Treatment
Ashesh Jani, MD, MSEE, FASTRO, Professor, Department of Radiation Oncology, Emory University
10:58 am Q & A
11:00 am Topic 6D: Overview of Surgical Treatment
Adam Feldman, MD, MPH, Assistant Professor of Surgery, Harvard Medical School; and Director, Combined Harvard Urologic Oncology Fellowship
11:12 am Q & A
11:14 am Topic 6E: NCCN Guidelines for Treatment of Localized Prostate Cancer
Kelvin A. Moses, MD, PhD
11:26 am Q & A
11:34 am – 1:19 pm LUNCH BREAK
1:19 pm SESSION III: POPULATION OF MEN WITH ADVANCED PROSTATE CANCER
Moderators:
Neil H. Bander, MD, Bernard & Josephine Chaus Professor of Urologic Oncology, Weill Cornell Medicine
.
..
David Nanus, MD, Mark W. Pasmantier Professor of Hematology and Medical Oncology in Medicine, and Director of the New York-Presbyterian Hospital – Weill Cornell Medicine Healthcare System Cancer Program
.
Daniel Petrylak, MD, Professor of Medicine, Director of Genitourinary Oncology and Co-Director of Signal Transduction Program, Yale University
.
.
1:34 pm Topic 1: Overview of Treatment for Advanced Prostate Cancer, including Oligometastatic and Systemic Disease
1:34 pm Topic 1A: Standard Treatment and Global Prostate Cancer Issues
Marc Garnick, MD, Director of Cancer Community Services, Network Development, BIDMC, Gorman Brothers Clinical Professor of Medicine at Harvard Medical School (HMS), Special Advisor, Oncologic Drugs Advisory Committee of the FDA
.
1:43 pm Q & A
1:45 pm Topic 1B: Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape
Paul Sieber, MD, President, Medical Director, Research, Lancaster Urology
2:44 pm Topic 1D: Bispecific T-Cell Engager (BiTE®) Platform for Immuno-Oncology
Michael Groaning, PhD, Global Medical Affairs Lead – Prostate Cancer, Amgen
2:56 pm Topic 1E: Epigenetic Modulations and Lineage Plasticity
Himisha Beltran, MD, Associate Professor of Medicine, Harvard Medical School and Director of Translational Research, Department of Medical Oncology, Dana-Farber Cancer Institute
.
3:08 pm Q & A
3:11 pm Topic 1F: Novel Treatment and Its Integration With Precision Diagnostics
3:23 pm Q & A
3:25 pm – 3:40 pm Panel Discussion: Standard and Emerging Treatment
3:40 pm – 4:00 pm COFFEE BREAK
4:00 pm Topic 2: Molecular and Multi-Modality Imaging and Theranostics
4:00 pm Topic 2A: Overview
Wolfgang Weber, MD, Professor and Chair, Department of Nuclear Medicine, Klinikum der Isar, Technical University of Munich, Germany
4:12 pm Q & A
4:14 pm Topic 2B: Practical Applications and Clinical Utility of the FDA-Approved PSMA PET Imaging Agent: Implications for Urology and Radiation Oncology
.Philip Koo, MD, Division Chief, Diagnostic Imaging, Banner MD Anderson Cancer Center
4:31 pm Q & A
4:33 pm Topic 2C: Defining Non-Metastatic and Oligometastatic Prostate Cancer vs. Systemic Disease
Jeremie Calais, MD, MSc, Assistant Professor, Clinical Research Program Director, Nuclear Medicine and Theranostics, University of California, Los Angeles
4:43 pm Q & A
4:45 pm Topic 2D: Current State of the Art and Future Vision in Theranostics
.
Philip Koo, MD
4:57 pm Q & A
5:00 pm – 5:10 pm Discussion of Molecular and Multi-Modality Imaging and Theranostics
5:10 pm – 6:00 pm GENERAL DISCUSSION
8:00 am SESSION IV: PRECISION DIAGNOSTICS AND EMERGING ROLE OF IMAGE-TARGETED, MINIMALLY INVASIVE TREATMENT: Multimodality Diagnostics for Improved Target Definition, Patient Selection, Monitoring & Outcomes
Moderators:
David Albala, MD, Chief of Urology, Crouse Hospital in Syracuse, New York; and Visiting Professor of Urology SUNY Downstate Health Sciences University, College of Medicine
Scott Eggener, MD, Bruce and Beth White Family Professor of Surgery and Radiology, Vice Chair, Section of Urology and Director, High Risk and Advanced Prostate Cancer Clinic, University of Chicago
.
Mitchell Sokoloff, MD, Professor and Chair of Urology, University of Massachusetts School of Medicine
Sadhna Verma, MD, Professor of Radiology, University of Cincinnati College of Medicine
.
Stephen Zappala, Clinical Assistant Professor, Department of Urology, Tufts University School of Medicine
.
8:15 am Overview
Jurgen Fütterer, MD, PhD, Interventional Radiologist, Professor of Image-guided Interventional Oncology, Radboud University Medical Center, Nijmegen, and Professor, Robotics and Mechanics Group, University of Twente, The Netherlands
8:26 am Q & A
8:28 am Current and Emerging Role of Radiogenomics in Risk Assessment
John Feller, MD, Chief Medical Officer, HALO Dx; and Assistant Clinical Professor of Radiology, Loma Linda University School of Medicine
8:40 am Q & A
8:42 am Image-Guided Laser Ablation – Experience at the University of Chicago
Aytekin Oto, MD, Professor and Chairman of Radiology, University of Chicago
8:51 am Q & A
8:53 am Follow-Up of Focal Cryoablation and Novel Pulse Sequences to Characterize the Treatment Zone
Daniel Margolis, MD, Associate Professor of Radiology and Director, Prostate MRI and Abdominal Imaging, Weill Cornell Medicine
9:05 am Q & A
9:07 am Image-Guided High Intensity Focal Ultrasound – Recent Clinical Trials
Steven Raman, MD, Clinical Professor of Radiology and Director of Prostate MR Imaging and Interventions, David Geffen School of Medicine, UCLA
9:18 am Q & A
9:20 am Whole Gland Transurethral Ultrasound Ablation – An Incision-Free Intervention With Real-Time Vision Performed Within The MR Suite
Robert Princenthal, MD, Medical Director, Prostate Imaging and Interventions, RadNet; President, Rolling Oaks Radiology
9:26 am Q & A
9:30 am – 10:00 am COFFEE BREAK
10:00 am Urologic Perspective on Clinical Utility and Outcomes
10:14 am Radiation Oncology Perspective
Daniel Y. Song, MD, Professor of Radiation Oncology and Molecular Radiation Sciences, and Co-Director, Prostate Cancer Multi-Disciplinary Clinic, Johns Hopkins University
10:26 am Q & A
10:30 am Emerging Data on the Current and Future Role of Image-Guided Treatment in Prostate Cancer Care
10:42 am Q & A
10:44 am – 11:00 am Panel Discussion: Image-Guided Treatment
11:00 am – 1:00 pm LUNCH BREAK
1:00 pm PANEL ON PRECISION CARE AND HEALTH DISPARITIES IN PROSTATE CANCER
Moderators:
Adam B Murphy, MD, MBA, MSCI, Assistant Professor, Department of Urology & Preventive Medicine, Northwestern Medicine – Feinberg School of Medicine, Affiliate Member of Institute for Global Health and Center for Community Health
Quoc-Dien Trinh, MD, Co-Director, Dana-Farber/Brigham and Women’s Prostate Cancer Program; Director, Ambulatory Clinical Operations, Division of Urological Surgery; and Associate Professor of Surgery, Harvard Medical School
1:45 pm PANEL ON BIOINFORMATICS, ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING FOR A MULTI- MODALITY DATA ANALYSIS FOR PRECISION DIAGNOSIS AND TREATMENT PLANNING
Moderators:
Paul Boutros, PhD, MBA
Arnold C Cinman, MD, FACS, Partner, Tower Urology; and Attending Urologist, Cedars-Sinai Medical Center, Los Angeles
Rakesh Shiradkar, PhD, Research Assistant Professor, Biomedical Engineering, Case Western Reserve University, Member, Case Comprehensive Cancer Center
1:45 pm Personalization of Prostate Cancer Care through Integration of Data
Ilya Gipp, MD, PhD, Oncology Solutions Subject Matter Expert, Philips
2:16 pm Q & A
2:18 pm Clinical Perspective on the Emerging and Potential Role of Machine Learning
Masoom Haider, MD
2:28 pm Q & A
2:30 pm Radiomics and Pathomics of Prostate Cancer: Diagnosis, Prognosis and Predicting Treatment Response
Anant Madabhushi, PhD, FAIMBE, FIEEE, FNAI, Donnell Institute Professor and Director, Center for Computational Imaging & Personalized Diagnostics, Departments of Biomedical Engineering, Urology, Radiology, Pathology, Radiation Oncology, Electrical, Comp & Systems Engineering, Computer & Data Sciences and Gen Med Sciences, Case Western Reserve University
2:42 pm Q & A
2:44 pm Artificial Intelligence
Liang Wang, MD, PhD, Professor, Attending Radiologist, Vice-Chairman for the Research and Development, Director of Urogenital Imaging, Department of Radiology, Beijing Friendship Hospital Capital Medical University
2:56 pm Q & A
2:59 pm Update on Multi-Factorial Nomograms
Amita Dave, PhD, Attending Physicist and Deputy Service Chief for Predictive Informatics, Director of Quantitative Imaging, Memorial Sloan Kettering Cancer Center
Andreas G. Wibmer, MD, Assistant Attending, Department of Radiology, Memorial Sloan Kettering Cancer Center
3:05 pm Q & A
3:07pm – 3:30 pm Panel Discussion: Bioinformatics, Artificial Intelligence and Machine Learning
3:30 pm – 3:50 pm: Presentation of Winning Abstracts:
Place #1: Safety and Feasibility of Intraprostatic Injection of CAN-2409 or Placebo followed by Valacyclovir in Patients on Active Surveillance for Prostate Cancer (ULYSSES Trial)
Place #2 (tied): Impact of 18F-Fluciclovine PET/CT on Plans for ADT in Patients with Biochemical Recurrence of Prostate Cancer; Analysis from Two Prospective Clinical Trials
Gerald L. Andriole, MD
Place #2 (tied): IsoPSA®: Clinical Performance of a Single Parameter, Structure-Based Test for High-Grade Prostate Cancer in a Large, Multicenter, Prospective Validation Trial
Mark Stovsky, MD, MBA, FACS, Chief Medical Officer, Cleveland Diagnostics, Inc.
Place #3: OSPREY and CONDOR: Results from Two Registrational Clinical Studies Assessing the Diagnostic Performance of Piflufolastat F 18 (PYLARIFY®) PET/CT in Patients with High-Risk and Recurrent Prostate Cancer
Bela Denes, MD, Vice President Global Medical Affairs, Lantheus Medical Imaging
3:50 pm – 5:30 pm SUMMARY PANEL DISCUSSION – SUMMIT HIGHLIGHTS
5:30 pm ADJOURN